![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » ALLERGY THERAPEUTICS MOVES FORWARD WITH POLLEN VACCINE TRIALS
ALLERGY THERAPEUTICS MOVES FORWARD WITH POLLEN VACCINE TRIALS
July 5, 2006
Allergy Therapeutics has concluded a successful end-of-Phase II meeting with the FDA for its ultra short course grass pollen allergy vaccine Pollinex Quattro.
Following a broad ranging review of Pollinex Quattro's preclinical, manufacturing and clinical data, and, subject to minor clarifications, the FDA has accepted the company's plans to conduct a single pivotal Phase III trial for registration of Pollinex Quattro Grass.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct